Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and ly3009120

sorafenib has been researched along with ly3009120 in 3 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(ly3009120)		Trials
(ly3009120)		Recent Studies (post-2010) (ly3009120)
6,5207305,25120019

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)ly3009120 (IC50)
Mitogen-activated protein kinase 13Homo sapiens (human)0.061
Tyrosine-protein kinase ABL1Homo sapiens (human)0.38
GTPase KRasHomo sapiens (human)0.15
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)0.023
Tyrosine-protein kinase FynHomo sapiens (human)0.091
Serine/threonine-protein kinase A-RafHomo sapiens (human)0.0297
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.31
Serine/threonine-protein kinase B-rafHomo sapiens (human)0.662
Ephrin type-A receptor 2Homo sapiens (human)0.02
Vascular endothelial growth factor receptor 2Homo sapiens (human)3.9
Tyrosine-protein kinase CSKHomo sapiens (human)0.29
Mitogen-activated protein kinase 8Homo sapiens (human)0.47
Mitogen-activated protein kinase 9Homo sapiens (human)0.47
Interleukin-1 receptor-associated kinase 1Homo sapiens (human)0.39
Mitogen-activated protein kinase 12Homo sapiens (human)0.061
Mitogen-activated protein kinase 10Homo sapiens (human)0.47
Ephrin type-B receptor 4Homo sapiens (human)0.1
Dual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)0.8
Mitogen-activated protein kinase kinase kinase 1Homo sapiens (human)0.098
Mitogen-activated protein kinase 11Homo sapiens (human)0.061
Mitogen-activated protein kinase 14Homo sapiens (human)0.061
Mitogen-activated protein kinase kinase kinase 20Homo sapiens (human)0.039
eIF-2-alpha kinase GCN2Homo sapiens (human)0.45
Mitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)0.97

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Agianian, B; Gavathiotis, E1
Abdel-Maksoud, MS; Ammar, UM; Oh, CH1
Abdel-Maksoud, MS; Ali, EMH; Ammar, UM; Mersal, KI; Oh, CH; Yoo, KH1

Reviews

2 review(s) available for sorafenib and ly3009120

ArticleYear
Current Insights of BRAF Inhibitors in Cancer.
    Journal of medicinal chemistry, 2018, 07-26, Volume: 61, Issue:14

    Topics: Animals; Drug Discovery; Humans; Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf

2018
Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents.
    European journal of medicinal chemistry, 2018, Oct-05, Volume: 158

    Topics: Animals; Antineoplastic Agents; Drug Discovery; Humans; MAP Kinase Signaling System; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; raf Kinases

2018

Other Studies

1 other study(ies) available for sorafenib and ly3009120

ArticleYear
Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting
    Bioorganic & medicinal chemistry, 2020, 06-01, Volume: 28, Issue:11

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Pyrroles; Structure-Activity Relationship

2020